Articles about us: Oblato Acquires Rights to Hearing Loss Drug (https://hearingreview.com/inside-hearing/research/hei)Bringing Back Silence (https://houghear.org/bringing-back-silence/) Noteworthy News: Our President, Dr. Elaine Hamm, was an invited speaker to the...
FOR IMMEDIATE RELEASE Potential Hearing Loss Drug Featured in The Scientist Otologic Pharmaceutics, in collaboration with the Hough Ear Institute, has developed a new drug that could restore hearing Through siRNA therapy, OPI/HEI scientists are able to regrow lost or...
Only Funded Application Among 73 Applicants Otologic Pharmaceutics, Inc. (OPI), in alliance with The Hough Ear Institute (HEI), announces the award of a Congressionally Directed Medical Research Programs (CDMRP) grant from the Department of Defense. The grant of $1.9...
Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders, announced the successful completion of single and multi-dose Phase...
Financing to Support Entry of OPI’s Lead Product Candidate – NHPN-1010 – into Clinical Testing First Half of 2014 OKLAHOMA CITY, April 3, 2014 /PRNewswire/ — Accele Venture Partners, the investing arm of life sciences accelerator Accele Biopharma, Inc.,...
